Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
18:516–519 © 1998 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 18, 1998

Author Index

Abkowitz JL, 27
Aboulafia DM, 460
Abrams DI, 80
Adam AM, 234
Affana G, 89
Albano F, 91
Allen J, 246
Allen S, 21
Alter MJ, S6
Altice FL, 341, 444
Alvarez JO, 21
Alvarez RB, 187
Alwano-Edyegu MG, 384
Ammassari A, 365
Andersen PK, 270
Anderson JE, S147
Andrade TM, 186
Anglin MD, 64
Annon J, 64
Antinori A, 365
Antonipillai I, 246
Ardito F, 39
Arrastia CD, 241
Arrigo S, 13
Atkins NS, 188
Avgeropoulos N, 13
Avila M, 190
Ayehunie S, 7
Aziz N, 162

Baba M, 316
Baba TW, 7
Baier M, 210
Bale J, 349
Baqi S, 73
Barbeau P, 46
Barker P, S147
Barreto J, 400
Bartsch GE, 80
Bastos FI, 488
Batts DH, 252
Beckett GA, S94, S145
Beer B, 210
Begtrup K, 270
Beilenson P, S120
Belay A, 7
Bélec L, 89
Benfield TL, 110
Bennett CL, 460
Bennetts A, 54
Benson CA, 454
Benveniste O, 389
Bergdahl S, 51
Bhadrakom C, 54
Bhatt SM, 234
Bigg D, S37
Biggar RJ, 270
Binquet C, 358
Biryahwaho B, 384
Biswas DK, 426
Blakeslee J, 1
Blanchette EA, 444
Blankaert D, 203
Blè C, 514
Bluthenthal RN, 505
Bogner J, 460
Bollinger RC, 277
Bongertz V, 488
Böni J, 399
Borromeo ME, 260
Boyer K, 86
Breilh D, 46
Briggs W, 246
Brown CR, 210
Brown G, 86
Bruneau J, S57
Bryz-Gornia V, 178
Bundy DAP, 188
Burns D, 86

Cajimat MNB, 260
Camp WL, 21
Campbell C, 384
Canadian Women's HIV Study Group, 479
Canani RB, 91
Carel BJ, 252
Carlson GF, 252
Carpenter CCJ, 260
Casano K, S82
Case P, S71, S94, S140
Casero R, 380
Castaldo A, 91
Castello-Branco LR, 488
Castilho EA, 488
Cato A III, 466
Cauda R, 39
Chaisson RE, 117
Chan-Tack K, 277
Chearskul S, 54, 323
Checko PJ, 444
Chen W, 397
Chen Y-MA, 299
Chesney MA, 136
Chiarelli F, 391
Chinaworapong S, 171
Chitwood DD, S25
Chiu J, 171
Chmiel JS, 495
Chu SY, S76
Cingolani A, 365
Clark L, 54
Clumeck N, 393
Comerford ST, S25
Conrad SH, 27
Contant C, 349
Contopoulos-Ioannidis DG, 126
Cooper ER, 221
Copenhagen AIDS Cohort, 110
Costa CI, 488
Costagliola D, 473
Coulibaly C, 210
Cruceta A, 398
Cuaresma C, 260
Cumberland WG, 332

Dabis F, 293, 358
De Clercq A, 293
De Clercq E, 316
de Gaetano K, 39
De Groot AS, 260
De Luca A, 365
De Maertelaer V, 393
de Martino M, 391
de Montalembert M, 473
Declich S, 514
Del Borgo C, 365
Delforge M-L, 393
Denisi R, 46
Denner J, 210
Depetris AR, 380
Des Jarlais DC, S52
Dessi C, 473

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
18:516–519 © 1998 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume 18, 1998

Author Index

Abkowitz JL, 27
Aboulafia DM, 460
Abrams DI, 80
Adam AM, 234
Affana G, 89
Albano F, 91
Allen J, 246
Allen S, 21
Alter MJ, S6
Altice FL, 341, 444
Alvarez JO, 21
Alvarez RB, 187
Alwano-Edyegu MG, 384
Ammassari A, 365
Andersen PK, 270
Anderson JE, S147
Andrade TM, 186
Anglin MD, 64
Annon J, 64
Antinori A, 365
Antonipillai I, 246
Ardito F, 39
Arrastia CD, 241
Arrigo S, 13
Atkins NS, 188
Avgeropoulos N, 13
Avila M, 190
Ayehunie S, 7
Aziz N, 162

Baba M, 316
Baba TW, 7
Baier M, 210
Bale J, 349
Baqi S, 73
Barbeau P, 46
Barker P, S147
Barreto J, 400
Bartsch GE, 80
Bastos FI, 488
Batts DH, 252
Beckett GA, S94, S145
Beer B, 210
Begtrup K, 270
Beilenson P, S120
Belay A, 7
Bélec L, 89
Benfield TL, 110
Bennett CL, 460
Bennetts A, 54
Benson CA, 454
Benveniste O, 389
Bergdahl S, 51
Bhadrakom C, 54
Bhatt SM, 234
Bigg D, S37
Biggar RJ, 270
Binquet C, 358
Biryahwaho B, 384
Biswas DK, 426
Blakeslee J, 1
Blanchette EA, 444
Blankaert D, 203
Blè C, 514
Bluthenthal RN, 505
Bogner J, 460
Bollinger RC, 277
Bongertz V, 488
Böni J, 399
Borromeo ME, 260
Boyer K, 86
Breilh D, 46
Briggs W, 246
Brown CR, 210
Brown G, 86
Bruneau J, S57
Bryz-Gornia V, 178
Bundy DAP, 188
Burns D, 86

Cajimat MNB, 260
Camp WL, 21
Campbell C, 384
Canadian Women's HIV Study Group, 479
Canani RB, 91
Carel BJ, 252
Carlson GF, 252
Carpenter CCJ, 260
Casano K, S82
Case P, S71, S94, S140
Casero R, 380
Castaldo A, 91
Castello-Branco LR, 488
Castilho EA, 488
Cato A III, 466
Cauda R, 39
Chaisson RE, 117
Chan-Tack K, 277
Chearskul S, 54, 323
Checko PJ, 444
Chen W, 397
Chen Y-MA, 299
Chesney MA, 136
Chiarelli F, 391
Chinaworapong S, 171
Chitwood DD, S25
Chiu J, 171
Chmiel JS, 495
Chu SY, S76
Cingolani A, 365
Clark L, 54
Clumeck N, 393
Comerford ST, S25
Conrad SH, 27
Contant C, 349
Contopoulos-Ioannidis DG, 126
Cooper ER, 221
Copenhagen AIDS Cohort, 110
Costa CI, 488
Costagliola D, 473
Coulibaly C, 210
Cruceta A, 398
Cuaresma C, 260
Cumberland WG, 332

Dabis F, 293, 358
De Clercq A, 293
De Clercq E, 316
de Gaetano K, 39
De Groot AS, 260
De Luca A, 365
De Maertelaer V, 393
de Martino M, 391
de Montalembert M, 473
Declich S, 514
Del Borgo C, 365
Delforge M-L, 393
Denisi R, 46
Denner J, 210
Depetris AR, 380
Des Jarlais DC, S52
Dessi C, 473

Detels R, 162, 332, 495
Devianne-Garrigue I, 46
Diaz C, 86, 221
Diaz T, S76
Dickinson BP, S140
Dieterich D, 394
Divekar AD, 277
Dockrell DH, 512
Doherty M, S120
Doherty MC, S11
Dominguez CE, 260
Dondero TJ, 384
Donfield S, 349
Dormont D, 389
Dourado I, 186
Downing RG, 384
Dube S, 178
Dupon M, 46

Edlin BR, 505
Eldred LJ, 117
Elion RA, 80
Epstein JS, 417
Erringer EA, 505
Esteban E, 178
Eugen-Olsen J, 110
Evandro Chagas Hospital AIDS Clinical Research Group, 488
Ewaniuk DS, 426

Fabiani M, 514
Fahey JL, 162
Farber C-M, 393
Farber CM, 203
Farine S, 393
Feldman L, 178
Ferrer JF, 178
Ferry JJ, 252
Fisher-Hoch S, 73
Flanigan TP, 260
Fleury HJA, 46
Floyd K, 234
Flynn C, 397
Flynn C, S30
Foley J, S45
Foongladda S, 323
Fridlund CA, 384
Friedland G, 435
Fruchter RG, 241

Gadkari DA, 277
Galena R, S145
Gallego S, 187
Galli L, 391
Galvão-Castro B, 186, 488
Gambertoglio J, 394
Gangakhedkar RR, 277
García F, 398
Garfein RS, S11
Garred P, 110
Gatell JM, 398
Gates EJ, 241
Gaydos C, 277
Gebbie KM, S144
Gee G, S89
Gendelman HE, 13
Gershon RRM, S20
Gibert CL, 80
Gifford AL, 136
Gilks CF, 234
Gilmore R, 454
Giordano M, 187
Giordano MO, 380
Giorgi JV, 162, 332
Girot R, 473
Glaser JB, 178
Gleghorn AA, S30, S89
Goebel FD, 229, 460
Goedert JJ, 155, 270
Goldberg B, 392
Golub RM, 460
Gonzales VM, 136
Gorsky R, S126
Gostin LO, S60
Gram GJ, 195
Granneman R, 466
Griffiths JK, 396
Gripp CBG, 488
Grivel P, 514
Grosser S, 162
Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA), 358
Gruskin L, S82
Guarino A, 91
Guimarães ML, 488
Gúinard S, 380
Gulbis B, 393
Guydish J, S37

Ha JC, 27
Hafalla JCR, 260
Hanchard B, 188
Hankins C, 479
Hankins CA, S57
Hansen J-ES, 195
Hanson C, 86, 221
Haq I-u, 73
Haque RA, 73
Hasan SN, 73
Hauck W, 88
Heimer R, S37
Heredia A, 417
Herman BD, 252
Hewlett IK, 417
Hirsch VM, 210
Hoffman P, 293
Holcomb K, 241
Hollinger FB, 409
Holtgrave DR, S133
Holzammer S, 210
Hoots WK, 349
Hoover DR, 495
Horton R, 246
Hsu A, 466
Huang H, 495
Hultin LE, 332

Ingegneri RM, S140
Ioannidis JPA, 126
Iversen AKN, 110

Jacobson MA, 394
Jacobsson B, 51
Jatlow P, 435
Jen I, 299
Jenkins RA, 171, 282
Jesdale B, S140
Jolly PE, 21
Jones JL, 289
Jones S, S45
Jones TS, S1, S45, S71, S76, S94, S102, S111, S120, S126, S133, S147
Joost M, 195
Junge B, S37, S82

Kaewkungwal J, 54
Kalish LA, 86
Kannangara GSK, 426
Kaplan AH, 332
Kaptué L, 89
Karagiorga M, 473
Karita E, 21
Katz D, S146
Kawalski R, 397
Kayani N, 73
Kelley B, 13
Kéou F-XM, 89
Keyl PM, S82
Khamboonruang C, 171
Khan AJ, 73
Khoshnood K, S37
Khurshid M, 73
Kirschner DE, 95
Kitsiripornchai S, 282
Knudsen K, 270
Koenig M, S120
Koester S, S139
Koppelhus U, 110
Kositanont U, 323
Kral AH, 505
Kuiken C, 488
Kumar P, 394
Kuriyama T, 307
Kurth R, 210

Lacoste D, 358
Ladner J, 293
Landay AL, 454
Landesman S, 86
Lansky A, 289
Laosakkitiboran J, 372
Lapointe N, 479
Lauder IJ, 409
Launer CA, 80
Laurent DD, 136
Lazzarini Z, S141

Le Grand R, 389
Lederer E, 229
Lee MG, 188
Lee SF, 417
Lena-Russo D, 473
Leng B, 46
Leonard J, 466
Leroy V, 293
Leucha W, 282
Lew JF, 221
Libonatti O, 190
Liesnard C, 203, 393
Likanonskul S, 323
Limpakarnjanarat K, 372
Limpitaks T, 282
Lin C-C, 299
Lin HJ, 409
Lindegren ML, 289
Lindo JF, 188
Linhares-Carvalho MI, 488
Liu K-L, S140
Liu Z, 332
Lobé MM, 89
Loch O, 229
Longshore D, 64
Lorig KR, 136
Loughran TP Jr, 178
Love JL, 178
Loveland K, 349
Luby SP, 73
Luckow B, 229
Lukwiya M, 514
Lurie P, S45, S126, S133

Macalino GE, S111
MacGowan R, S147
Machuca R, 195
Maeder M, 349
Mahoney E, 349
Maiman M, 241
Makino M, 316
Malo A, 229
Manalo MA, 260
Manna B, 162
Manopaiboon C, 54
Marchioli CC, 178
Marimoutou C, 358
Marique T, 203
Markowitz LE, 282
Martin C, 260
Martinez LC, 380
Marum E, 384
Mas A, 417
Massad LS, 454
Mastro TD, 54, 372
Matthews R, 241
Maturano E, 187
Matzen E, 86
Mauclère P, 89
Mayer KH, 260
Mbanya D, 89
McCance-Katz EF, 435
McCormick JB, 73
McCoy CB, S25
Medeot S, 187
Medeot SI, 380
Meehan T, S71
Mehendale SM, 277
Mehr R, 95
Melbye M, 270
Mendez HA, 221
Metsch LR, S25
Mhashilkar AM, 426
Michael RA, 171
Middaugh L, 13
Miles J, S102
Mills DA, S145
Miró JM, 398
Mitchell PS, 512
Moberg L, 51
Mock PA, 372
Mokotoff E, S76
Montag H, S82
Monterroso ER, S11
Moore RD, 117
Morgado MG, 488
Morgan PA, 171
Morse LJ, S143
Morse SA, 372
Mostashari F, 341, 444
Mottet NK, 27
Moyer LA, S6
Mpoudi-Ngollé E, 89
Muñoz A, 495
Murri R, 365
Muurahainen N, 80

Nabi N, 73
Nagata S, 307
Naretto E, 380
Nates S, 187
Nates SV, 380
Ndumbe P, 89
Nelson KE, 397
Nelson KE, S11
Neves I Jr, 488
Nielsen C, 195
Nielsen JO, 195
Nishanian P, 162
Nitayaphan S, 171
Nkengasong J, 89
Nolan PA, S140
Noll G, 1
Nopkesorn T, 372
Norley S, 210
Nosbisch C, 27
Nyiraziraje M, 293

O'Brien TR, 155
Oh LM, 426
Okada Y, 316
Olsen R, 1
O'Neill CH, S141
Orantia L, 260
Ortona L, 39, 365
Otieno LS, 234
Otten RA, 384

Pampuro S, 190
Pardee AB, 426
Parent D, 203
Pasha O, 73
Pellegrin I, 46
Pellegrin J-L, 46
Peralta LM, 190
Perelson AS, 95
Persidsky Y, 13
Persing DH, 512
Pezza JA, 426
Pezzotti P, 365
Phillips JF, 21
Piergies AA, 466
Pinkerton SD, S133
Pirronti T, 39
Pitt J, 221
Plesker R, 210
Poiesz BJ, 178
Poland GA, 512
Pomeroy C, 512
Pregnancy and HIV Study Group, 293
Pumarola T, 398

Qian J, 466
Quinn TC, 277

Ragnaud J-M, 46
Rahman ZS, S111
Rainey PM, 435
Ramirez BL, 260
Rayfield MA, 384
Read JS, 221
Rebulla P, 473
Recalde Y, 187
Reinhart B, 229
Remis RS, S57
Rich JD, S140
Rich K, 221
Riengrojpitak S, 323
Riley E, 341
Riley E, S120
Rinaldi D, 380
Risbud AR, 277
Robinette R, 27
Robinson RD, 188
Rosenberg PS, 155, 270
Rossi ME, 391
Ruangyuttikarn C, 171
Rud E, 190
Ruppenthal GC, 27
Ruprecht RM, 7
Ryan LL, S146
Rydman R, 454

Saarloos MN, 454
Sackett GP, 27
Sahaphong S, 323

Salhi Y, 473
Salla R, 89
Salomón H, 190
Sangkharomya S, 282, 372
Santiago EG, 260
Santiago ML, 260
Sattler F, 246
Schlöndorff D, 229
Schmid S, 372
Schoenbaum EE, S141
Schønning K, 195
Schüpbach J, 399
Scoppettuolo G, 365
Selwyn PA, 341, 444
Sempala SDK, 384
Serufilira A, 21
Sha BE, 454
Shaffer N, 54
Shapshak P, S25
Shepherd M, 277
Shields D, S145
Shomphe L, S126
Sileoni S, 187
Simonart Th, 203
Singh R, 444
Siriwasin W, 54
Siwak EB, 409
Smeriglio V, 221
Smith L, S120
Smith TF, 512
Sönnerborg A, 51
Sontirat A, 171
Soriano V, 417
Spagnuolo MI, 91
Spear GT, 454
Spira R, 358
Springer KW, S111
Stehbens J, 349
Stewart S, 460
Stinson TJ, 460
Stone VE, 145
Stricker RB, 392
Strickland SR, 512
Sugimoto A, 307
Supplement to HIV/AIDS Surveillance Group, S76
Suruga Y, 316
Suteewan W, 54
Sutthent R, 323
Sweat M, 372

Tacconelli E, 39
Takemori T, 307
Tanaka H, 316
Tanaka M, 307
Tanguay S, 444
Tapko J-B, 89
Taylor JMG, 162
Terry Beirn Community Programs for Clinical Research on AIDS, 80
The Women and Infants Transmission Study Group, 86, 221
Thomas DL, S11
Tius MA, 426
Toce P, S146
Tran T, 479
Triozzi PL, 1
Tsunetsugu-Yokota Y, 307
Tumbarello M, 39
Tuomala R, 86
Turner BJ, 88
Tyor WR, 13

Unadkat JD, 27
Ungchusak K, 282

Vallejo A, 417
Van de Perre P, 293
Van Vooren JP, 203
Van Vooren J-P, 393
Vaslin B, 389
Veloso VG, 488
Vermund SH, 21
Vidal C, 398
Vierucci A, 391
Vlahov D, 397
Vlahov D, S1, S11, S82, S89, S111, S120, S133
Vomvouras S, 466
von Roenn J, 460

Wainberg M, 190
Walli R, 229
Wan P-CT, 289
Wank R, 229
Wanprapa N, 323
Warrell DA, 234
Wasi C, 323
Watson J, 221
Weinstein B, S76, S102, S146
Weiss HL, 21
Weniger BG, 372
Werenne J, 203
Wheeler DA, 80
Wollan PC, 512
Wortley P, 289
Wright LN, S144
Wright-De Agüero L, S30, S102
Wu AW, 117

Yacci MR, 380
Yagi T, 307
Yagita H, 307
Yasuda S, 307
Yellin F, 155
Young NL, 372
Yu PS, 299
Yunis NA, 145

Zekeng L, 89
Zhang H, 397
Zlatkes R, 190
zur Megede J, 210

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
18:520–525 © 1998 Lippincott-Raven Publishers, Philadelphia

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology Volume 18, 1998

Subject Index

Abortion, therapeutic, in HIV-infected women, 479
Acquired immunodeficiency syndrome (AIDS)
  cardiac manifestations of, 145
  epidemic of in Cameroon (letter), 89
  onset, immune activation markers changes before, 162
  prevention of in injection drug users, S52
  retinol serum levels and viral load in, 21
  susceptibility differences in, 270
Adherence, with antiretroviral therapy, 341
Adolescents, mortality predictors with hemophilia in, 349
Africa
  chorioamnionitis and pregnancy outcome in, 293
  HIV-1 prevalence trends among risk groups in (letter), 514
  retinol serum levels and viral load in, 21
  rising case load of adult HIV-related disease in, 234
African green monkeys, simian immunodeficiency virus in, 210
AIDS clinical trial group 262, methadone effects on zidovudine disposition in, 435
AIDS wasting syndrome, low dihydrotestosterone and, 246
AIDS-related disorders, changing disease patterns in focal brain lesions and, 365
Amerindians, in HTLV-IIB infected, 178
Anthracyclines, cost-effectiveness of for Kaposi's sarcoma, 460
Antiprotease therapy, nutritional status and (letter), 393
Antiretroviral therapy
  acceptance and adherence with, 341
  prophylactic, adherence to, 117
  rapid change in use of, 358
Anti-*Toxoplasma* prophylaxis, for toxoplasmic encephalitis, 365
Apoptosis, of activated CD4 T-cells, 307
Argentina
  first report of HIV-2 infection in (letter), 190
  HTLV-I/II seropositivity in high-risk populations of (letter), 187
  picobirnavirus in, 380
Arthrospira platensis extract, in HIV-1 replication inhibition, 7
Aseptic drug preparation, in HIV prevention, S1
Asia
  HIV antibody seroprevalence and associated risk factors in, 73
  HIV infection impact on families with HIV-infected women, 54
  HIV-1 subtype E incidence in military conscripts in, 372
Attenuated *nef*-truncated SIVmac251, responses to in macaque PBMCs (letter), 389
Attitudes, in HIV-infected female prisoners, 341
Autologous lymph node lymphocytes, in adoptive immunotherapy of FeLV, 1
Autologous neutralizing antibody response, in long-term HIV-1 infection, 195
Azidothymidine (AZT)
  fetal, infant, and maternal toxicity of, 27
  in inhibition of HIV-1 replication, 426

Bacterial pneumonia, in HIV-infected patients, 39
Baltimore
  community support for needle exchange in, S82
  HIV/HTLV-II coinfection and CD4 T-cell count in injection drug users in (letter), 397
  needle and syringe drop boxes in, S120
Bangkok, impact of HIV infection on on family with HIV-infected women, 54
Behavior change
  education for, 136
  in HIV-infected female prisoners, 341
  of young men in Thailand, 282
Behavioral abnormalities, in SCID mice with HIV encephalitis, 13
Blood-borne infection
  among injection drug users (letter), S139
  control of among injection drug users, S20
  deregulation of for medical use of syringes and needles to prevent (letter), S143
  syringe exchange programs and, S133
Brazil
  HTLV-I/II and HIV in injecting drug users of (letter), 186
  molecular epidemiology of HIV-1 infection in, 488

California, illegal syringe exchange and risk behaviors among injection drug users in, 505
Canada, sterile syringes in HIV prevention in, S57
Cardiac manifestations, of HIV/AIDS, 145
Cardiomyopathy, in HIV/AIDS infection, 145
Case load, rising in Nairobi, 234
CCR5, long-term slow progressors for, 229
CCR2 polymorphism, disease progression and CD4 T-cell count and, 110
CD38 antigen, CD8 T-cell activation and, 332
CD4 T-cell count
  chemokine receptor CCR2b 64I polymorphism and, 110
  HIV/HTLV-II coinfection and in injection drug users (letter), 397
CD4 T-cells
  Fas/FasL interaction in apoptosis of, 307
  serum immune activation markers and, 162
  simian immunodeficiency virus and, 210
CD8 T-cells
  activation in HIV-1 disease, 332
  serum immune activation markers and, 162
  simian immunodeficiency virus and, 210
Central nervous system lymphoma, changing disease patterns in focal brain lesions in, 365
Cervical cancer, HIV infection as risk factor for, 241
Cervicovaginal lavage, for chemokines in genital tract, 454
Chancroid, incidence in military conscripts in Thailand, 372
Chemokine receptor polymorphism
  CCR2b 64I, CD4 T-cell count and disease progression and, 110
  in long-term HIV-1 infection, 195
Chemokines
  CCR5 and receptors of, 229
  in genital tract of HIV-seropositive and -seronegative women, 454

Children
mortality predictors in hemophiliac, 349
nucleoside analogues and T-cell subset counts in (letter), 391, 392
Chlamydia trachomatis, in female sex workers in Taiwan, 299
Chorioamnionitis, pregnancy outcome and, 293
Cigarette smoking, maternal-child HIV transmission and (letter), 86, 88
Clinical trials, of zidovudine-methadone interactions, 435
Clonotypic T-cell populations, in peripheral blood, 178
Cohort study, of HIV susceptibility differences, 270
Combination therapy
drug interactions in, 466
in inhibition of HIV-1 replication, 426
Community support, for needle/syringe exchange programs, S82
Community-based needle disposal programs, S111
Compliance, with antiretroviral and pneumocystis prophylaxis, 117
Condom use
among military conscripts in Thailand, 372
in Thailand, 282
Connecticut
increasing access to sterile syringes in (letter), S146
syringe prescription laws in, S102
Contraception, in HIV-infected women, 479
Coreceptor use, of V3 loop and protease gene, 417
Cost-effectiveness analysis
of liposomal anthracyclines, 460
of needle and syringe exchange programs, S126, S133
Counseling, optimizing of, 384
Cyclosporin A, long-term use of in HIV-induced pityriasis lichenoides chronica (letter), 396
Cytomegalovirus infection
foscarnet treatment for, 46
glutamic acid hydrochloride and bioavailability of oral ganciclovir with (letter), 394

Daunorubicin, in Kaposi's sarcoma treatment, 460
Delavirdine-indinavir drug interactions, 252
Denmark
chemokine receptor CCR2b 64I polymorphism in, 110
HIV susceptibility differences in homosexual men in, 270
Desferrioxamine, in HIV-1 infection in thalassemic patients, 473
Developing countries, HIV prevention vaccine trials in, 171
Diabetes mellitus, safe needle and syringe disposal and, S111
Diagnosis, heat-denatured p24 antigen in (letter), 399, 400
Diarrhea, picobirnavirus in HIV-infected patients with, 380
Didanosine, pharmacokinetic interaction of with ritonavir, 466
Dihydrotestosterone, AIDS wasting syndrome and, 246
Disease progression
antiretroviral agents and, 358
chemokine receptor CCR2b 64I polymorphism and, 110
in heterozygous vs. wild-type slow progressors, 229
in pediatric HIV, 221
serum ferritin and desferrioxamine levels and in thalassemic patients, 473
weight loss as predictor of, 80
Diversity, HIV, single-strand conformation polymorphism analysis of, 409
Doxorubicin, in Kaposi's sarcoma treatment, 460
Drug interactions
of delavirdine and indinavir, 252
of ritonavir and didanosine, 466
of zidovudine and methadone, 435
Drug paraphernalia
legislation on in Oregon (letter), S144
in parenteral HIV transmission, S25
sharing of among injection drug users, 505
Drug preparation equipment, in parenteral HIV transmission among injection drug users, S25
Drug sharing, in parenteral HIV transmission among injection drug users, S25

Economics, of needle and syringe exchange programs, S126
Education, to improve self-management in symptomatic HIV men, 136
Encephalitis, HIV, behavioral abnormalities with, 13
Endocarditis, in HIV/AIDS infection, 145
Endothelial cells, metalloproteinase release by in Kaposi's sarcoma, 203
Epidemiology
of HIV-1 in Brazil, 488
of HIV-1 in Philippines, 260
in homosexual men, 155
Erratum
Determinants of HIV infection among female commercial sex workers in northeastern Thailand (1996;12:500–7), 192
Serum retinol and HIV-1 RNA viral load in rapid and slow progressors (1998;18:21–6), 401
Ethical issues, in HIV prevention vaccine trial, 171
Europe, chemokine receptor CCR2b 64I polymorphism in, 110

Family, impact of HIV infection on, 54
Fas/FasL interaction, in apoptosis of activated CD4 T cells, 307
Feline leukemia virus infection, adoptive immunotherapy of, 1
Ferritin, serum levels in HIV-1 infection in thalassemic patients, 473
Fetal toxicity, of zidovudine, 27
Flow cytometry, for CD8 T-cell activation, 332
Focal brain lesions, changing disease patterns in, 365
Foscarnet
anti-HIV-1 activity of, 51
HIV-1 plasma load and, 46
France, rapid change in use of antiretroviral agents in, 358

Ganciclovir, glutamic acid hydrochloride and bioavailability of (letter), 394
Genital tract, chemokines in, 454
Genital ulcers, HIV-1 DNA shedding in, 277
Glutamic acid hydrochloride, in bioavailability of oral ganciclovir with cytomegalovirus disease (letter), 394
Group O isolates, V3 loop and protease gene of, 417

Haemophilus ducreyi, incidence in military conscripts in Thailand, 372
Haemophilus influenzae type B immunization, HIV viremia and (letter), 512
Health care, for HIV-infected patients in France, 358
Health care system, rising case load of adult HIV-related disease in, 234
Heart disease, in HIV/AIDS infection, 145
Hematologic toxicity, of zidovudine during pregnancy, 27
Hemophilia, mortality predictors in children and adolescents with, 349
Hepatitis C virus
prevalence and incidence of in young injection drug users, S11
preventing among injection drug users, S6
Herpes simplex virus 2 (HSV-2), in female sex workers in Taiwan, 299
Herpes simplex virus, incidence in military conscripts in Thailand, 372
Heteroduplex mobility assay, for HIV-1 epidemiology in Brazil, 488
High-risk populations, HTLV-I/II seropositivity in (letter), 187
HIV-1
apoptosis of activated CD4 T-cells in, 307
chemokine receptor polymorphism and autologous neutralizing antibody response in, 195

chorioamnionitis and pregnancy outcome in Africa, 293
DNA shedding of in genital ulcers, 277
evolution of in thalassemic patients, 473
in female sex workers in Taiwan, 299
foscarnet effects on, 51
genomic regions of for single-strand conformation polymorphism analysis of HIV-1 quasispecies, 409
group O isolates, V3 loop and protease gene of, 417
long-term slow progressors for, 229
maternal viral load and perinatal transmission of, 126
molecular epidemiology of in Brazil, 488
plasma load of, foscarnet and, 46
prevalence of among risk groups in Uganda (letter), 514
quasispecies, single-strand conformation polymorphism analysis of, 409
subtypes of, 260
thymus in, 95
HIV-2, in Argentina (letter), 190
HIV antibody seroprevalence
in sex workers, drug users, and prisoners in Pakistan, 73
HIV encephalitis, behavioral abnormalities with, 13
HIV predictors, among newly sentenced male prisoners, 444
HIV prevention
arrests for possession of syringes and, S71
in injection drug users, S1, S52
needle and syringe drop boxes and, S120
sterile syringes in, S57
HIV-1 replication
inhibition by aqueous extract of *Spirulina platensis*, 7
inhibition of, 426
HIV-1 RNA
foscarnet effects on, 46, 51
longitudinal levels in cohort of homosexual men, 155
HIV-1 RNA viral load
following tuberculin skin test (letter), 398
in rapid and slow progressors, 21
HIV-1 subtype B, in Brazil, 488
HIV-1 subtype D, in Brazil, 488
HIV-1 subtype E
incidence in military conscripts in Thailand, 372
V3 sequence diversity in, 323
HIV testing services, optimizing of, 384
HIV vaccine trials, motivation, recruitment, and screening for, 171
HIV viremia, *Haemophilus influenzae* type B immunization and (letter), 512
HIV-associated dementia complex, in SCID mice, 13
Homosexual men
HIV susceptibility differences in, 270
longitudinal HIV-1 RNA levels in, 155
Homosexuality, STDs and in military conscripts in Thailand, 372
Human immunodeficiency virus (HIV) infection
advance cervical cancer risk and, 241
bacterial pneumonia in, 39
HTLV-I/II and in injecting drug users (letter), 186
impact on family of HIV-infect women, 54
susceptibility differences in, 270
Human immunodeficiency virus (HIV)-seropositivity
chemokines and, 454
Haemophilus influenzae type B immunization and (letter), 512
Human immunodeficiency virus/Human T-lymphocytic virus II (HIV/HTLV-II) coinfection
CD4 cell count and in injection drug users (letter), 397
Human T-lymphocytic virus IIB (HTLV-IIB), clonotypic T-cell populations in peripheral blood of, 178
Human T-lymphocytic virus I/II (HTLV-I/II)
in female sex workers in Taiwan, 299
HIV and in injecting drug users (letter), 186
immunomodulatory effects on strongyloidiasis (letter), 188
seropositivity for in high-risk populations in Argentina (letter), 187

Immune activation
CD8 T-cells and, 332
markers of prior to AIDS onset, 162
Immune mediators, chemokines in genital tract and, 454
Immunodeficiency
adoptive immunotherapy of, 1
CD8 T-cells and, 332
Immunology, thymus in, 95
Immunomodulation, of strongyloidiasis with concurrent HTLV-I infection (letter), 188
Immunotherapy, adoptive, for feline leukemia virus infection, 1
Incubation period, in AIDS development, 270
India, HIV-1 DNA shedding in genital ulcers in, 277
Indinavir-delavirdine drug interactions, 252
Infants
disease progression in, 221
V3 sequence diversity of HIV-1 subtype E in, 323
Infection control, single-use syringes in, S20
Inflection points, prior to AIDS onset, 162
Injection drug user packets, for pharmacists (letter), S146
Injection drug users
arrests and incarceration of for syringe possession, S71
blood-borne infection among (letter), S139
economic analysis of pharmacy-based programs needle/syringe for, S126
in female prisoners, 341
hepatitis C virus in, S11
HIV antibody seroprevalence and associated risk factors in, 73
HIV prevention among, S57
HIV prevention in, S1, S6, S52
HIV risk and syringe reuse among (letter), S140
HIV/HTLV-II coinfection and CD4 T-cell count in (letter), 397
HTLV-I/II and HIV in (letter), 186
illegal syringe exchange and risk behaviors among, 505
legal environment impeding access to sterile syringes in, S60
long-term trends in self-reporting of, 64
needle and syringe drop boxes for, S120
needle hygiene and sources for (letter), S147
needle/syringe exchange programs for, S82, S89
parenteral transmission among, S25
preventing blood-borne infection in (letter), S143
in prisons, 444
safe needle and syringe disposal and, S111
single-use syringes in infection control among, S20
sterile syringe access for, S30, S37, S45, S94
syringe exchange programs for, S37
syringe prescription for (letter), S141
syringe prescription laws and, S94, S102
syringe sharing among, S76
Insulin-like growth factor-1, AIDS wasting syndrome and, 246
Interleukin-2, in adoptive immunotherapy of FeLV, 1
Interleukin-1β, response to acute infection with attenuated *nef*-truncated or pathogenic SIVmac251 (letter), 389
Interleukin-6, response to acute infection with attenuated *nef*-truncated or pathogenic SIVmac251 (letter), 389
Intestinal malabsorption, zidovudine (letter), 91
Isolation, of HIV-1 group O, 417

Kaposi's sarcoma
cost-effective treatment of, 460
foscarnet treatment for, 46
liposomal anthracyclines in treatment of, 460
metalloproteinase-9 release by cells of, 203
survival factors in, 495
Kernel density analysis, of HIV-1 quasispecies, 409

Laws
drug paraphernalia (letter), S144

HIV prevention and, S71
on needle/syringe prescription, S89, S94
versus public health, S60
for syringe prescription (letter), S141
on syringe reuse (letter), S140
syringe sharing and HIV prevention, S76
Letters to editor
1989-1996 HIV-1 prevalence trends among different risk groups in Gulu District, North Uganda, 514
absence of effect of glutamic acid hydrochloride on the bioavailability of oral ganciclovir in AIDS patients with cytomegalovirus disease, 394
associations among HTLV-I, HTLV-II, and HIV in injecting drug users in Salvadore, Brazil, 186
changes in HIV-1 RNA viral load following tuberculin skin test, 398
cigarette smoking and maternal-child HIV transmission, 86
cigarette smoking and maternal-child HIV transmission: authors' reply, 88
comparing IL-6, TNF-α, and IL-1β responses to acute infection with attenuated *nef*-truncated or pathogenic SIVmac251 in macaque peripheral blood mononuclear cells, 389
deregulation of syringes and needles for medical use and to prevent the spread of blood-borne pathogens among illicit injection drug users, S143
do nucleoside analogues directly influence T-lymphocyte subset counts? The pediatric model, 391
do nucleoside analogues directly influence T-lymphocyte subset counts? The pediatric model: authors' reply, 392
effect of *Haemophilus influenzae* type B immunization on HIV viremia in HIV-seropositive adults, 512
first report of HIV-2 infection in Argentina, 190
following the blood: syringe reuse leads to blood-borne virus transmission among injection drug users, S139
HIV/HTLV-II coinfection and $CD4^+$ cell count controlling for plasma HIV viral load in injection drug users in Baltimore, 397
HTLV-I/II seropositivity in populations at high risk for HIV-1 infection in Cordoba City, Argentina, 187
immunomodulatory effects of concurrent HTLV-I infection in strongyloidiasis, 188
intestinal malabsorption and zidovudine bioavailability, 91
Maine removed criminal penalties fro syringe possession in 1997 after allowing sale of syringes without a prescription in 1993, S145
needle hygiene and sources of needles for injection drug users: data from a national survey, S147
in New York City, syringe laws and regulations deter physicians and pharmacists from prescribing and selling syringes to persons who may be injection drug users, S141
nutritional status and antiprotease therapy, 393
Oregon's exclusion of syringes from its 1987 drug paraphernalia law was an HIV prevention measure, S144
peer education of pharmacists and supplying pharmacies with IDU packets to increase injection drug users' access to sterile syringes in Connecticut, S146
sensitivity of heat-denatured p24 antigen in the diagnosis of pediatric HIV infection, 399
sensitivity of heat-denatured p24 antigen in the diagnosis of pediatric HIV infection: author's reply, 400
strict syringe laws in Rhode Island are associated with high rates of reusing syringes and HIV risks among injection drug users, S140
successful long-term use of cyclosporin A in HIV-induced pityriasis lichenoides chronica, 396
trends of AIDS epidemic in Cameroon, 1986 through 1995, 89
Liposomal anthracyclines, cost-effectiveness of in AIDS-related Kaposi's sarcoma treatment, 460
Macaca nemestrina, zidovudine toxicity during pregnancy in, 27
Maine
access to sterile syringes in, S94
syringe possession in (letter), S145
Malignancies, in secondary AIDS, 495
Massachusetts, arrests for possession of syringes in, S71
Maternal toxicity, of zidovudine administered throughout pregnancy, 27
Maternal viral load, in perinatal transmission, 126
Maternal-child HIV transmission
cigarette smoking and (letter), 86, 88
V3 sequence diversity and, 323
Mental illness, among male prisoners, 444
Metalloproteinase-9, constitutive release of by Kaposi's sarcoma cells, 203
Methadone, effects on zidovudine disposition, 435
β_2-Microglobulin, prior to AIDS onset, 162
Molecular epidemiology
of HIV-1 in Brazil, 488
of HIV-1 subtypes, 260
Monocyte-derived macrophages, in HIV-1 O group isolates, 417
Montreal, sterile syringes in HIV prevention in, S57
Mortality predictors, in HIV-infected children and adolescents with hemophilia, 349
Motivation, in preventive vaccine trial volunteers, 171
Murine AIDS, prevention of by (*R*)-9-(2-phosphonylmethoxypropyl) adenine, 316
Myocarditis, in HIV/AIDS infection, 145

Nairobi, rising case load of adult HIV-related disease in, 234
Needle disposal, pilot project for, S120
Needle drop boxes, pilot project for, S120
Needle exchange programs, S37
community support for, S82
cost-effectiveness of, S133
economic analysis of, S126
in HIV prevention, S57
pharmacists' attitude toward, S89
pharmacists in, S45
pilot project for, S120
Needles
deregulation of for medical use (letter), S143
hygiene of (letter), S147
safe disposal of, S111
single-use, S52
sterile, legal environment impeding access to, S60
syringe prescription laws and, S94
Needlestick injuries, safe disposal and, S111
Neonates, simian immunodeficiency virus in, 210
Neopterin, prior to AIDS onset, 162
New York City, laws for syringe prescription in (letter), S141
Nucleoside analogues, T-cell subset counts and (letter), 391, 392
Nutritional status, antiprotease therapy and (letter), 393

Opportunistic infection
survival factors and, 495
weight loss and, 80
Oregon, drug paraphernalia law in (letter), S144

p24 antigen, heat-denatured, sensitivity of in diagnosis of pediatric HIV infection (letter), 399, 400
Pakistan, HIV antibody seroprevalence and associated risk factors in, 73
Parenteral transmission, among injection drug users, S25
Pathogenesis
CD8 T-cells in, 332

of simian immunodeficiency virus in newborn African green monkeys, 210
Pediatric AIDS/HIV
disease progression in, 221
heat-denatured p24 antigen in diagnosis of (letter), 399, 400
thymus in, 95
Pericarditis, in HIV/AIDS infection, 145
Perinatal transmission
impact on family of, 54
maternal viral load and, 126
Peripheral blood mononuclear cells, in HTLV-IIB infected Amerindians, 178
Pharmacies
in needle/syringe exchange, S45, S126, S133
syringe sales by, S82, S89, S94, S102
Pharmacists, peer education of (letter), S146
Pharmacokinetics
of indinavir and delavirdine, 252
of ritonavir and didanosine, 466
of zidovudine and methadone, 435
Philippines, molecular epidemiology of HIV-1 in, 260
Phylogenetic analysis, of V3 loop and protease gene, 417
Picobirnavirus, detection in HIV-infected patients with diarrhea, 380
Pityriasis lichenoides chronica, long-term use of cyclosporin A in (letter), 396
Plasma viral load, in heterozygous vs. wild-type slow progressors, 229
PMEA, in murine AIDS prevention, 316
Pneumocystis carinii, adherence to prophylaxis for, 117
Pneumocystis prophylaxis, adherence to, 117
Pneumonia, in HIV-infected patients, 39
Polyacrylamide gel electrophoresis (PAGE) technique, for picobirnavirus detection, 380
Polymerase chain reaction
for HIV-1 DNA shedding in genital ulcers, 277
for HTLV-IIB infected Amerindians, 178
Predictors, of disease progression in infants with HIV infection, 221
Pregnancy
chorioamnionitis and outcome of in HIV-infected African women, 293
sexual behavior and outcome of in HIV-infected women, 479
zidovudine prescription during, 289
zidovudine toxicity during, 27
Prevalence trends, among risk groups in Uganda (letter), 514
Prevention
among injection drug users, S30, 505
cost-effectiveness of increased access to syringes and needles, S133
deregulation of for medical use of syringes and needles for (letter), S143
of hepatitis C virus in injection drug users, S6
of HIV infection among male prisoners, 444
needle and syringe drop boxes and, S120
needle/syringe exchange programs in, S37, S82
PMPA in, 316
single-use needles and syringes in, S52
syringe prescription laws and, S102
syringe sharing and, S76
Primary cells, HIV-1 replication inhibition and, 7
Prisoners
HIV antibody seroprevalence and associated risk factors in, 73
HIV predictors among, 444
women, antiretroviral therapy for, 341
Prognostic indicators/markers
for bacterial pneumonia in HIV infection, 39
CD8 T-cells as, 332
Prostitutes
HIV-1, HTLV-I, and other STDs in, 299
HIV antibody seroprevalence and associated risk factors in, 73
STD among in Thailand, 372
Protease gene, tropism, coreceptor use, and phylogenetic analysis of, 417
Pseudomonas aeruginosa, in HIV infection, 39
Public health policy
versus drug law enforcement, S60
in drug law enforcement and HIV prevention, S71
on syringe prescription, S94

Quantitative fluorescence, for CD8 T-cell activation, 332

Race, in HIV infection among male prisoners, 444
Randomized controlled trial, of education in improving self-management skills, 136
Rapid HIV antibody testing, in Uganda, 384
5-α Reductase, AIDS wasting syndrome and, 246
Research participation, motivation, recruitment, and screening for, 171
Retinol, serum levels and HIV-1 RNS viral load, 21
Retrovirus, adoptive immunotherapy of, 1
Reverse transcriptase inhibitor, in murine AIDS prevention, 316
Rhode Island, laws on syringe reuse in (letter), S140
Risk, long-term trends in self-reporting of, 64
Risk behavior
among HIV-infected injection drug users, S76
among injection drug users, 505
HIV-1 prevalence and in Uganda (letter), 514
in injection drug users, 505
long-term trends in self-reporting of, 64
in parenteral HIV transmission among injection drug users, S25
of young men in Thailand, 282
Risk factors
for advance cervical cancer, 241
for bacterial pneumonia in HIV infection, 39
HIV-1 DNA shedding in genital ulcers and, 277
in sex workers, drug users, and prisoners in Pakistan, 73
Ritonavir, pharmacokinetic interaction of with didanosine, 466
RNA levels, in homosexual men, 155
(*R*)-9-(2-phosphonylmethoxypropyl)adenine, in murine AIDS prevention, 316
Rwanda, retinol serum levels and viral load in, 21

SCID mice, behavioral abnormalities in with HIV encephalitis, 13
Self-management, education to improve, 136
Self-reporting, long-term trends in, 64
Sequencing, of HIV-1 O group isolates, 417
Serum immune activation markers, changes prior to AIDS onset, 162
Sex workers
HIV-1, HTLV-I, and other STDs in, 299
HIV antibody seroprevalence and associated risk factors in, 73
Sexual behavior
pregnancy outcome and in HIV-infected women, 479
of young men in Thailand, 282
Sexual transmission, of HIV infection, 372
Sexually transmitted diseases
in female sex workers in Taiwan, 299
incidence in military conscripts in Thailand, 372
in prisons, 444
Shooting galleries, in parenteral HIV transmission, S25
Simian immunodeficiency virus (SIV), in newborn African green monkeys, 210
Single-strand conformation polymorphism analysis, of HIV-1 quasispecies, 409
SIVmac251, responses to in macaque PBMCs (letter), 389
Slow progressors, long-term heterozygous versus wild-type, 229
Social support, for HIV-infected women in Thailand, 54

Spirulina platensis extract, in HIV-1 replication inhibition, 7
Staphylococcus aureus, in HIV infection, 39
Sterility, in infection control among injection drug users, S20
Streptococcus pneumoniae, in HIV infection, 39
Strongyloidiasis, immunomodulatory effects of HTLV-I on (letter), 188
Substance abuse
  legislation and, S71
  needle and syringe drop boxes and, S120
  needle/syringe exchange programs and, S89
  safe needle and syringe disposal and, S111
  syringe prescription laws and, S102
  in U.S. metropolitan areas, S30
Surveillance, of syringe sharing among HIV-infected drug users, S76
Survival factors, in secondary AIDS, 495
Survival predictors
  in HIV-infected children and adolescents with hemophilia, 349
  weight loss as, 80
Symptoms, education to improve self-management of, 136
Syphilis
  in female sex workers in Taiwan, 299
  incidence in military conscripts in Thailand, 372
Syringe drop boxes, pilot project for, S120
Syringe exchange programs, S37
  cost-effectiveness of, S133
  in Oakland, California, 505
Syringe sharing
  among HIV-infected injection drug users, S76
  blood-borne infection and (letter), S139
  hepatitis C virus and, S11
  in parenteral transmission, S25
  prevention of, S37
Syringes
  arrests for possession of, S71
  decriminalizing possession of (letter), S145
  deregulation of for medical use (letter), S143
  pharmacy sales of, S82, S89, S102
  repeal of prescription laws, S94
  safe disposal of, S111
  sales of (letter), S145
  single-use, S52
  single-use, in infection control, S20
  sterile
    access to, S102
    cost-effectiveness of increasing access to, S133
    economic analysis of programs to increase access to, S126
    feasibility of one-time use of, S30
    in HIV prevention, S1, S57
    increasing access to (letter), S146
    for injection drug users, S45
    legal environment impeding access to, S60
    in Maine, S94
  strict laws on reuse of (letter), S140
  use and reuse of, S37

Taiwan, HIV-1, HTLV-I, and other STDs in female sex workers in, 299
T-cell counts, nucleoside analogues and (letter), 391, 392
T-cell receptors, in peripheral blood of HTLV-IIB infected Amerindians, 178
Testosterone, AIDS wasting syndrome and, 246
Thailand
  HIV prevention vaccine trials in, 171
  HIV-1 subtype E incidence in military conscripts in, 372
  impact of HIV infection on on family with HIV-infected women, 54
  sexual behavior of men in, 282
Thalassemia, serum ferritin, desferrioxamine, and HIV-1 development in, 473
Thymus, in pediatric HIV-1 infection, 95
Time trends, in focal brain lesions, 365
Tissue inhibitor, of metalloproteinases, 203
Toxoplasmic encephalitis, changing disease patterns in focal brain lesions in, 365
Transmission
  of HIV-1 quasispecies, 409
  of HIV-1 subtypes, 260
  maternal viral load and, 126
  maternal-child, 323
    cigarette smoking and (letter), 86, 88
  parenteral, among injection drug users, S25
Tropism, of V3 loop and protease gene, 417
Tuberculin skin test, HIV-1 RNA viral load following (letter), 398
Tumor necrosis factor-α
  inhibitor of in HIV-1 replication inhibition, 426
  response to acute infection with attenuated *nef*-truncated or pathogenic SIVmac251 (letter), 389

Uganda
  HIV-1 prevalence trends among risk groups in (letter), 514
  optimizing of HIV counseling and testing services in, 384
United States, HIV susceptibility differences in homosexual men in, 270

V-β gene rearrangement, in HTLV-IIB infected Amerindians, 178
V3 loop, tropism, coreceptor use, and phylogenetic analysis of, 417
V3 sequence diversity, of HIV-1 subtype E in infected mothers and infants, 323
Vertical transmission
  cigarette smoking and (letter), 86, 88
  disease progression in infant cohorts with, 221
  V3 sequence diversity and, 323
Viral load
  CD8 T-cells and, 332
  following tuberculin skin test (letter), 398
  foscarnet and, 46
  in long-term slow progressors, 229
  perinatal transmission and, 126
  in rapid and slow progressors, 21
  of simian immunodeficiency virus in newborn African green monkeys, 210
Viral shedding, in genital ulcers, 277
Vitamin A, in rapid and slow progressors, 21

Wasting, as predictor of survival, 80
Weight loss
  low dihydrotestosterone and, 246
  as survival and disease progression predictor, 80
Women
  chemokines in genital tract of, 454
  chorioamnionitis and pregnancy outcome in, 293
  in correctional facility, antiretroviral therapy in, 341
  impact of HIV on families of in Thailand, 54
  sexual behavior in, 479
  zidovudine prescription for during pregnancy, 289
Women and Infants Transmission Study, 221, 409

Zidovudine
  fetal, infant, and maternal toxicity of, 27
  intestinal malabsorption and bioavailability of (letter), 91
  methadone effects on disposition of, 435
  prescription trend for pregnant women, 289